Skip to main content

Table 4B Clinical benefit achieved from subsequent lines of endocrine therapy in patients with de novo resistance to 2nd line endocrine therapy following clinical benefit to 1st line endocrine therapy

From: "Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer

Lines of Endocrine therapy 3 rd line 4 th line
N 6 2
N with CB (%) 3 (50.0) 1 (50.0)
Median DOR with CB (months) 15.0 (13–32) 9.0
N still receiving treatment 0 0
  1. CB = Clinical Benefit; DOR = Duration of Response